Back to top
more

MediWound (MDWD)

(Delayed Data from NSDQ)

$17.59 USD

17.59
47,822

+1.18 (7.19%)

Updated Apr 24, 2024 04:00 PM ET

After-Market: $17.48 -0.11 (-0.63%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value C Growth D Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 42% (147 out of 252)

Industry: Medical - Drugs

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for MDWD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

0 items in cart

MediWound Ltd. [MDWD]

Reports for Purchase

Showing records 1 - 20 ( 37 total )

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 1

03/22/2024

Company Report

Pages: 7

Strong Adoption Following NexoBrid Launches; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 2

02/13/2024

Daily Note

Pages: 3

EscharEx Demonstrated Paradigm-shifting Potential in VLU Debridement; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 10.00

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 3

01/31/2024

Daily Note

Pages: 114

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 4

01/30/2024

Daily Note

Pages: 115

2024 Top Picks: Seeing Important Turnaround Year While Watching the Macro

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 150.00

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 5

01/16/2024

Company Report

Pages: 7

NexoBrid to Drive Growth in 2025 and Beyond; New $28 PT; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 25.00

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 6

11/22/2023

Company Report

Pages: 6

Optimized Entry and Exit Levels for MDWD 112223

Provider: Stock Traders Daily

Analyst: Research Department

Price: 12.50

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 7

11/22/2023

Company Report

Pages: 8

Demand for NexoBrid Increased Worldwide; Phase 3 Study of EscharEx to Enroll in 2H24; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 8

09/21/2023

Company Report

Pages: 7

FDA Clears NexoBrid for Commercialization; New PT of $26; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 9

08/17/2023

Company Report

Pages: 8

Launch of NexoBrid and Initiation of Pivotal Phase 3 of EscharEx Expected in 1Q24; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 10

05/31/2023

Company Report

Pages: 8

Expanded Manufacturing Facility to Sustain NexoBrid Growth; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 11

03/17/2023

Company Report

Pages: 7

NexoBrid Launch Imminent; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 12

02/07/2023

Daily Note

Pages: 110

HCW 2023 Top Picks: Seize the Opportunities

Provider: H.C. Wainwright & Co., Inc.

Analyst: Research Department

Price: 75.00

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 13

01/03/2023

Company Report

Pages: 7

NexoBrid Approved; PT Adjusted to $23; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 14

11/16/2022

Company Report

Pages: 8

NexoBrid BLA Under Review; EscharEx to Enter Pivotal Phase 3; Lower PT to $5.50; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 15

08/10/2022

Company Report

Pages: 7

Potential NexoBrid Approval in 2023; Lower PT to $6; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 16

07/14/2022

Daily Note

Pages: 4

Nuggets From KOL Event on EscharEx; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 17

07/08/2022

Daily Note

Pages: 3

EscharEx Continues to Achieve Positive Results; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 18

05/18/2022

Company Report

Pages: 7

Robust EscharEx Phase 2 Data; Change of Guard Not Impactful; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 19

03/18/2022

Company Report

Pages: 7

EscharEx Regulatory Pathway Decision in 2H22; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 12.50

Research Provided by a Third Party

Company: MediWound Ltd.

Industry: Medical - Drugs

Record: 20

01/24/2022

Daily Note

Pages: 4

EscharEx Scores Big in VLU; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: RAMAKANTH S

Price: 5.00

Research Provided by a Third Party